KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Common Equity (2016 - 2024)

Historic Common Equity for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $46.5 billion.

  • Novartis Ag's Common Equity rose 549.11% to $46.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $46.5 billion, marking a year-over-year increase of 549.11%. This contributed to the annual value of $46.5 billion for FY2025, which is 549.11% up from last year.
  • As of Q4 2025, Novartis Ag's Common Equity stood at $46.5 billion, which was up 549.11% from $44.8 billion recorded in Q3 2025.
  • Over the past 5 years, Novartis Ag's Common Equity peaked at $67.8 billion during Q4 2021, and registered a low of $38.2 billion during Q3 2023.
  • Over the past 5 years, Novartis Ag's median Common Equity value was $48.7 billion (recorded in 2021), while the average stood at $50.2 billion.
  • As far as peak fluctuations go, Novartis Ag's Common Equity soared by 2197.12% in 2022, and later tumbled by 3719.83% in 2023.
  • Quarter analysis of 5 years shows Novartis Ag's Common Equity stood at $67.8 billion in 2021, then decreased by 12.38% to $59.4 billion in 2022, then decreased by 21.33% to $46.8 billion in 2023, then dropped by 5.61% to $44.1 billion in 2024, then increased by 5.49% to $46.5 billion in 2025.
  • Its Common Equity stands at $46.5 billion for Q4 2025, versus $44.8 billion for Q3 2025 and $42.1 billion for Q2 2025.